COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring. |
University of Cambridge > Talks.cam > Winton Discussions > Meeting the challenges of cancer through nanotechnology.
Meeting the challenges of cancer through nanotechnology.Add to your list(s) Download to your calendar using vCal
If you have a question about this talk, please contact Nalin Patel. A Winton teatime discussion hosted by Dr Quentin Harmer, CTO of Endomagnetics. The company, spun out form UCL in 2007, is exploring the use of nanotechnology for medical applications and Quentin will introduce their work and some of the future challenges in cancer research. Abstract: Around the world the incidence of cancer is growing, and with it the demand for better, faster and cheaper solutions for diagnosis and treatment. Endomagnetics was founded to solve healthcare challenges through the application of nanotechnology and advanced magnetic sensing technology. The SentiMag and Sienna+ device system was developed to increase access to the standard of care in breast cancer staging by providing an alternative approach to locating sentinel lymph nodes. The Endomagnetics system avoids the requirement for traditional radioisotopes in sentinel lymph node biopsy, improving workflow and costs while increasing availability of the standard of care. This talk will touch upon some of the challenges of developing a new nanotechnology-based product and translating it to the clinic. Bio: Dr Quentin Harmer is CTO at Endomagnetics Ltd with more than fifteen years experience in leading the development of advanced medical devices and drug-device combination products. Quentin joined Endomagnetics from Vectura Group plc where he served as Project Director responsible for the development of novel inhaler products. Prior to joining Vectura he served at Cambridge Consultants Ltd, working with client companies in the healthcare, industrial, consumer products, and automotive industries. He is an inventor on numerous patents, and many of these have been licensed to leading pharmaceutical companies. Quentin holds a PhD in Engineering Design and an MA in Engineering, both from the University of Cambridge. He is a Chartered Engineer and member of the Institute of Engineering Technology. This talk is part of the Winton Discussions series. This talk is included in these lists:
Note that ex-directory lists are not shown. |
Other listsExplore Islam Week 2014 (EIW) Centre for Smart Infrastructure & Construction Cosmology lists CSLB - SPARC joint workshop The Homi Bhabha Lecture Isotope Coffee: Geochemistry and Petrology Seminars Department of Earth SciencesOther talksInformation Theory, Codes, and Compression Scaling of tissue proportions to body size during vertebrate development TODAY Foster Talk - Integrin-associated adhesion complexes and their role in mechanotransduction Organic Bio-Electronic systems: from tissue engineering to drug discovery The MHC ligandome of two contagious cancers within the Tasmanian devil population, Devil Facial Tumour 1 and Devil Facial Tumour 2 Giant response of weakly driven systems |